New pill shows promise for rare liver disease

NCT ID NCT03333928

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants took either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower a liver enzyme called ALP, which is a marker of liver damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HTD1801 (a drug taken as tablets)

What this could lead to

If it works, this could point toward a treatment to control PSC and improve liver health.

What could go wrong

This is an early Phase 2 trial with only 59 people, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS (PSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arizona Liver Health

    Chandler, Arizona, 85224, United States

  • Arizona Liver Health

    Tuscon, Arizona, 85711, United States

  • Aspen Woods Clinic

    Calgary, Alberta, T3H 0V5, Canada

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Cumberland Research Associates

    Fayetteville, North Carolina, 28304, United States

  • Florida Research Institute

    Lakewood Rch, Florida, 34211, United States

  • Fresno Clinical Research Center

    Fresno, California, 93720, United States

  • Gastro One

    Germantown, Tennessee, 38138, United States

  • Gastrointestinal Associates

    Flowood, Mississippi, 39232, United States

  • Keck School of Medicine of USC

    Los Angeles, California, 90033, United States

  • Mercy Medical Center

    Baltimore, Maryland, 21202, United States

  • Michigan Medicine University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • Mount Sinai - Icahn School of Medicine

    New York, New York, 10029, United States

  • Pinnacle Clinical Research

    Austin, Texas, 78746, United States

  • Pinnacle Clinical Research

    San Antonio, Texas, 78229, United States

  • South Denver Gastroenterology, PC

    Englewood, Colorado, 80113, United States

  • Swedish Medical Center

    Seattle, Washington, 98104, United States

  • Toronto Centre for Liver Disease, Toronto General Hospital

    Toronto, Ontario, M5G 2C4, Canada

  • University of Colorado, Denver

    Aurora, Colorado, 80045, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Washington

    Seattle, Washington, 98104, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27157, United States

  • Walter Reed National Military Medical Center

    Bethesda, Maryland, 20889, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Yale School of Medicine

    New Haven, Connecticut, 06520, United States